These findings support the potential role of RAS and BRAF in the pathogenesis of medullary thyroid cancer and suggest that evaluation of RAS mutations in sporadic RET negative MTC patients can be useful to select targeted therapies (18). Here, RET is linked to medullary thyroid gland carcinoma.